Good afternoon, sir. First question is on the biologics part. You explained how FY27 and FY28 could be good growth years for the business. I just wanted to understand what is the number in terms of revenue and say EBITDA loss for FY26 and when do we expect the breakeven in this biologics business?
If you can answer which year can we expect the business to breakeven and start contributing in terms of profitability also?
Good afternoon, sir. My question is on the GLP-1 side. Sir, you talked about some uncertainty for Q3 -- understand a bit longer, say, Q4 and Q1.
Yes. This should be better.
Yes. Good morning. Two questions. One is on our two products, Liraglutide and Teriparatide. We were supposed to launch these products in Europe for a while now. Can you talk about the revised timelines? Do we expect this quarter it will take two, three more quarters? And what is causing this delay? That is question number one.
So, is it expected in, say, first half of this year or next second half of this year, both the launches?
Yes, sir. So, my question was on the seeker side. So, when we talk about INR1,500 Crore kind of order expected in next Quarter, we are not including the seeker production orders, right? That production order will be after that , that is one clarification I want. And the question is also on the...
Yes. Is this better?
My first question is on super-tech. So, any guidance on that project and can it start?
Second question is on running order book. So, you said by end of this year, we'll be at INR44,000 crores, assuming 10,000 additional by the end of this year. But I want these numbers for FY '27 and FY '28. Can we this running order book to be around INR60,000, INR70,000 crores in the next 1 to 2 years?
My first question is -- you talked about Netaji Nagar having INR1,900 crores work in pipeline and Sarojini Nagar remaining INR2,700 crores. So do you expect -- is there a chance some of it will come in FY '26 or most of it will come in FY '27?
Okay. So even if you assume, say, 1, 2 quarters delay, so at least by second half of next year, most of this will be done, Netaji Nagar and Sarojini Nagar, both.
My first question is on Kavach. So when you talk about today we are at R&D stage, and by June, July, you expect this R&D stage to be over. So is my understanding correct that, normally, a company needs to supply the hardware and software prototypes. So that y ou will supply by the June, July 2025?
And sir, normally, after that, there is normally a field trial of like 5,000, 10,000 hours. So we'll be starting that field trials by June, July?
Ya, good evening sir. The question is on our diabetic portfolio. So, if you can talk about how well are we placed as a company to take the advantage of the upcoming GLP-1 opportunity? So, I believe we have some FTF filings in that. So, in terms of launch, are we ready whenever the expiry happens, we'll be there? Do you think this product category can be like a US$ 300 to 500 million kind of category for the next five years?
In terms of the important dosages, are we present in all of them, if you can talk about the same?
My first question is on our diabetes portfolio. So , if you can talk about how are we place d to take the advantage of the upcoming GLP -1 opportunity -- will we be participating in both the oral and injectable form, if you can talk about the same?
On this part only , so oral, do we plan to file the FTF on that si de? And also, do you think this market itself for us can become like a $100 million market plus over the next five years as a company?
Good evening, Sir. My first question is on the defense side and then on the product side.
Yes, I have a question on product side also sir. On the defense side, if you can give an update last call you talked about some potential tenders in BMP upgrade and fuses as well, and on the SDR and night vision. If you can update on all the three, four products.
My first question is on our GLP -1 portfolio. If you can talk about do we have a first to file in both, say, Liraglutide and Semaglutide and when can we start seeing some revenues? And do you think this can be a big opportunity for our company?
If you can just talk about the opportunity. Do you think this can be a big opportunity for our company and when can we expect some revenues from this division?